The administration unveiled the Great Healthcare Plan promising lower drug costs and direct payments to ACA enrollees, but industry executives told reporters the policy lacks operational detail. The plan would lock in discounts negotiated via most‑favored‑nation (MFN) style deals and shift federal subsidies toward individuals. Concurrently, the administration is pressing Congress to codify its MFN agreements, a move that would transform voluntarily negotiated manufacturer discounts into statutory obligations. Policymakers and pharma leaders warned that legal and legislative hurdles remain and that commercial implications could be significant for market access and pricing strategies. Stakeholders from insurers, manufacturers and congressional offices are positioning for negotiations; the industry is monitoring whether voluntary MFN deals will become permanent law or remain administration policy. Sources: MedCity News reporting and contemporaneous White House communications.